Sing2016 M2SR H3N2 Monovalent Influenza Vaccine
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Sing2016 M2SR H3N2 Monovalent Influenza Vaccine, covering 2023-06-15 to 2023-06-15. Get the full timeline:
Most recent: Clinical Trial Update: Safety and Immunogenicity of the Sing2016 M2SR H3N2 Monovalent Influenza Vaccine in Adults Ages 50 to 85 Years Old [Phase 1]